Speaker Profile
Vice President of the Center for Observational Research, Amgen
Biography
Brian is a global expert in pharmacoepidemiology and real-world data (RWD), with over 25 years of experience in industry and academia. At Amgen, he leads a team of over 150 professionalsincluding epidemiologists, biostatisticians, and data scientistsfocused on generating high-quality real-world evidence (RWE) to inform healthcare decision-making and support patient care. His team has conducted research across multiple countries, addressing drug safety, effectiveness, supporting regulatory approvals and post-marketing safety commitments, and describing disease burden and unmet need.Brian oversaw the development of Amgen's global RWD platform, housing data on more than 350 million lives, and successfully integrated the FDA Sentinel System to enhance safety surveillance efforts. He is an Adjunct Professor of Epidemiology at UCLA and has authored over 90 peer-reviewed publications on pharmacoepidemiology, disease epidemiology, and advanced methods for controlling confounding in drug safety research.
Session Abstract – PMWC 2026 Silicon Valley
Track Co-Chairs:
- William Oh, Yale Cancer Center
- David Reese, Amgen
Patient-centric data, such as Real-World Evidence (RWE) and Real-World Data (RWD), has become critical in reshaping drug development and healthcare decision-making. Over the last few years, regulatory agencies like the FDA and EMA have increasingly embraced RWE/RWD for decision-making processes, influencing everything from new drug indications to post-marketing surveillance. The integration of RWE and RWD is not only supporting clinical trial design and regulatory approvals, but also enabling precision medicine by providing deeper insights into patient subpopulations and their outcomes
Sessions:
- TBA
